Shanna Arnold, PhD


Postdoctoral Fellow, Dr. Zijlstra’s Lab, Vanderbilt University

Dr. Arnold started as a graduate student in the laboratory of Rolf Brekken at UT Southwestern, where she studied the role of the tumor microenvironment in cancer progression and metastasis. Her specific research emphasis was then, and now, on molecular mechanisms that control tumor progression.

Dr. Arnold is currently a postdoctoral research fellow in the laboratory of Dr. Zijlstra at Vanderbilt University where her projects focus on tumor cell adhesion, migration and metastasis. She spearheads the translation of these mechanistic findings to the development of clinically relevant biomarkers. The current focus is on the clinical relevance of a cell adhesion molecule, ALCAM, and the mechanism by which is controls motility.

Relevant Publications

Oakley F, Woods M, Arnold S & Young P. Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products. Transfusion. (epub Aug 2014) PMID: 25145580

Hansen A, Arnold S, Ming J, Ketova T, Merkel A, Sterling J, Hayward S, Elefteriou F, & Zijlstra A. ALCAM/CD166 is a TGFβ responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Research. 2014 Mar 1;74(5):1404-15. PMID: 24385212

Palmer TD, Martínez-Vasquez CH, Hebron K, Jones-Paris C, Arnold SA, Chan SM, Chalasani V, Gomez-Lemus JA, Williams AK, Chin JL, Giannico GA, Ketova T, Lewis JD & Zijlstra A. Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer Research. 2014 Jan 1;74(1):173-87. PMID: 24220242 PMCID: PMC3947299

Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CA, Gilger MA, Washington MA, Fan KH, Shyr Y, Beauchamp RD & Zijlstra A. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. Cancer Research. 2013 May 15;73(10):2955-64. PMID: 23539446 PMCID: PMC3660148

Arnold SA, Rivera LB, Carbon JG,Toombs JE, Chang CL , Bradshaw AD & Brekken RA. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation. PLoS One. 2012; 7(2):e31384. PMID: 22348081 PMCID: PMC3279359

Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, Sage EH, Puolakkainen P, Bradshaw AD & Brekken RA. Lack of host SPARC enhances vascular function and accelerates metastasis in an orthotopic murine model of pancreatic carcinoma. Disease Models and Mechanisms. 2010 Jan-Feb; 3(1-2):57-72. PMID: 20007485 PMCID: PMC2806901 [Selected as journal cover]

Arnold SA & Brekken RA. SPARC: a matricellular regulator of tumorigenesis. Journal of Cell Communication and Signaling. 2009 3:255-273. PMID: 19809893 PMCID: PMC2778590

Bull-Phelps SL, Carbon JG, Miller AF, Castro-Rivera E, Arnold SA, Miller DS, Brekken RA & Lea JS. Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. American Journal of Obstetrics and Gynecology. 2009 Feb; 200(2):180.e1-7. PMID: 18992864

Arnold SA*, Mira AE*, Muneer SE*, Korpanty G, Beck AW, Holloway SE, Mañes S & Brekken RA. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Experimental Biology and Medicine; 2008; 233(7):860-873. (* Equal Contribution) PMID: 18445772 PMCID: PMC2459223 [Cited as SEBM Best Paper for 2008 in the category experimental biology/basic research]